BREAKING
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 9 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 10 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 11 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 3 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 4 days ago Synopsys Q1 2026 Earnings Results 4 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 4 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 4 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 9 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 10 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 11 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 3 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 4 days ago Synopsys Q1 2026 Earnings Results 4 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 4 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 4 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago
ADVERTISEMENT
AlphaGraphs

Earnings: Highlights of Abbott Laboratories’ (ABT) Q4 2025 report

Medical device maker Abbott Laboratories (NYSE: ABT) on Thursday reported a 4% increase in sales for the fourth quarter of FY25. The company also issued its full-year 2026 guidance. Sales increased 4.4% year-over-year to $11.46 billion in the fourth quarter, with a 3% growth in organic sales. For fiscal 2026, Abbott expects organic sales growth […]

$ABT January 22, 2026 1 min read
NYSE
$ABT · Earnings

Medical device maker Abbott Laboratories (NYSE: ABT) on Thursday reported a 4% increase in sales for the fourth quarter of FY25. The company also issued its full-year 2026 guidance. Sales increased 4.4% year-over-year to $11.46 billion in the fourth quarter, with a 3% growth in organic sales. For fiscal 2026, Abbott expects organic sales growth […]

admin · January 22, 2026

Medical device maker Abbott Laboratories (NYSE: ABT) on Thursday reported a 4% increase in sales for the fourth quarter of FY25. The company also issued its full-year 2026 guidance.

Abbott Laboratories Q4 2025 Earnings

Sales increased 4.4% year-over-year to $11.46 billion in the fourth quarter, with a 3% growth in organic sales. For fiscal 2026, Abbott expects organic sales growth to be in the range of 6.5% to 7.5%.

Excluding special items, net earnings rose to $1.50 per share in the December quarter from $1.34 per share in the prior-year quarter. The company projects full-year adjusted earnings in the range of $5.55 per share to $5.80 per share, which reflects 10% growth at the midpoint

On a reported basis, net income was $1.78 billion or $1.01 per share in the fourth quarter, vs. $9.2 billion or $5.27 per share in Q4 2024.

ADVERTISEMENT

“In 2025, we expanded margins and achieved double-digit earnings per share growth, our new product pipeline was highly productive, and we took important strategic steps to shape the company for the future,” said Robert Ford, Abbott’s CEO.

ADVERTISEMENT